Arcus Biosciences, Inc. · NYSE:RCUS

Arcus Biosciences — Q1 2024 Earnings Presentation

66 slides from Arcus Biosciences's earnings presentation, May 8, 2024

  1. Slide 1: Combining to Cure

    COMBINING TO CURE ® Arcus is at the forefront of designing combination therapies, with best-in-class potential, in the relentless pursuit of cures for cancer. CORPORATE PRESENTATION May 8, 2024

  2. Slide 2: Forward-looking Statements/Safe Harbor

    Forward-looking Statements/Safe Harbor This presentation contains forward-looking statements about Arcus Biosciences, Inc. (“we,” “Arcus” or the “Company”) made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements regarding events or results

  3. Slide 3: Late-stage Portfolio of Differentiated Assets, Highly Productive R&D Engine

    Arcus Has Created a Late-stage Portfolio of Differentiated Assets, Fueled by a Highly Productive R&D Engine FUNDING INTO LATE-STAGE COMPANY MULTIPLE PHASE 3 2027 STUDIES FOR DOM IN LUNG Line of sight to first & UPPER GI in 2024+ ~$1.1B in cash, product approval (dom/zim) cash equivalents 2 new progr

  4. Slide 4: Broad Portfolio of Investigational Molecules with Best-in-Class Potential

    Arcus Has a Broad Portfolio of Investigational Molecules with Best- in-Class Potential Targeting Huge Market Opportunities DIFFERENTIATED ANTI-TIGIT + DIFFERENTIATED SMALL MOLECULES NEXT-GENERATION PROGRAMS ANTI-PD-1 BACKBONE AB801: Potential best-in-class casdatifan: Potential best-in-class HIF- do

  5. Slide 5: Three Late-Stage Programs with Multiple Upcoming Milestones

    Three Late-Stage Programs with Multiple Upcoming Milestones; Earlier-Stage Portfolio Maturing Program Disease Study Line & Regimen Ph 1/1b Ph 2 Ph 3 Upcoming Milestones 1L, PD-L1 all-comers, metastatic • 2024: Enrollment completion dom + zim + chemo vs pembro + chemo Perioperative lung cancer IN PLA

  6. Slide 6: Our Partnerships Expand & Accelerate Opportunities in Arcus's Portfolio

    Our Partnerships Greatly Expand & Accelerate Opportunities Inherent in Arcus’s Portfolio 10-YEAR COLLABORATION • Gilead has opted into 5 molecules to date -- shares costs for studies within the joint development plan • Arcus retains U.S. co-commercial rights COLLABORATION FOR JAPAN AND OTHER TERRITO

  7. Slide 7: Domvanalimab in Non-Small Cell Lung Cancer and Upper GI Cancers

    Domvanalimab in Non-Small Cell Lung Cancer and Upper GI Cancers 7 © Arcus Biosciences 2024

  8. Slide 8: Domvanalimab, an Fc-Silent anti-TIGIT

    Domvanalimab, an Fc-Silent anti-TIGIT DOMVANALIMAB Dom may have important Most clinically advanced Fc-silent differences over Fc-enabled anti-TIGIT antibody in development, anti-TIGIT competitors with best-in-class potential  Peripheral Treg numbers do not ZIMBERELIMAB decrease with dom + zim, but

  9. Slide 9: Two De-Risking Phase 2 Datasets for Dom Plus Zim Regimens

    Two De-Risking Phase 2 Datasets for Domvanalimab Plus Zimberelimab Regimens Were Presented in 2023 1L Gastric/EAC/GEJ 1L PD-L1 high NSCLC dom + zim + FOLFOX (n=40) dom + zim vs. zim vs. etruma + dom + zim (n=150) Update at • PD-L1-high (TAP ≥5%) for DZ + FOLFOX*: • PFS HRs: − ORR/cORR: 80% / 73% − 0

  10. Slide 10: Phase 3 Program Targeting Significant Market Opportunities

    Phase 3 Program for Dom-Based Combinations is Targeting Significant Market Opportunities STUDY LEAD SPONSOR SETTING US PATIENT POPULATION1 1L NSCLC, PD-L1 All comers 119k patients Stage 3 NSCLC, 21k patients unresectable, PD-L1≥1% 1L Gastric/GEJ/EAC 25k patients $10B+ addressable Multi-billion reven

  11. Slide 11: Summary of EDGE-Gastric Arm-A1 Results and Dom Plus Zim Program in Upper GI

    Summary of EDGE-Gastric Arm-A1 Results and Domvanalimab Plus Zimberelimab Clinical Program in Upper GI Cancers Data presented at the November 2023 ASCO Plenary Series, based on data cut off of September 4, 2023. Updated data to be presented at ASCO 2024 11 © Arcus Biosciences 2024

  12. Slide 12: Phase 2 Trial of Dom and Zim Combinations in Advanced Upper GI

    Phase 2 Trial to Evaluate Dom and Zim Combinations in Advanced Upper GI Malignancies ARMS NOT RANDOMIZED, ENROLLED SEQUENTIALLY ARM A1: COHORT A dom + zim Q4W + FOLFOX Q2W 1L N ≈ 40 per arm ARM A2: zim Q4W + FOLFOX Q2W KEY ELIGIBILITY CRITERIA PRIMARY ENDPOINTS: • Locally advanced • Safety unresecta

  13. Slide 13: Results for Arm A1 in 1L Metastatic Gastric/GEJ/EAC

    Results for Arm A1 in 1L Metastatic Gastric/GEJ/EAC Were Presented at ASCO Plenary in November 2023 KEY ELIGIBILITY CRITERIA • First-line locally advanced PRIMARY ENDPOINTS: unresectable or metastatic gastric/GEJ/EAC • Safety • Investigator ORR • Measurable disease per N ≈ 40 dom 1600 mg Q4W RECIST

  14. Slide 14: Encouraging ORR and 6-Month PFS Results

    Encouraging ORR and 6-Month PFS Results • As of the 4 September 2023 data cutoff, 24 patients (59%) continued on study treatment PD-L1 High* PD-L1 Low* Efficacy-Evaluable (TAP ≥5%) (TAP <5%) N=41 N=15 N=24 n (%) n (%) n (%) ORR, % [95% CI] 80 [52, 96] 46 [26, 67] 59 [42, 74] Confirmed ORR, % [95% CI

  15. Slide 15: Almost All Patients Experience Some Benefit, Irrespective of PD-L1 Status

    Almost All Patients Experience Some Benefit, Irrespective of PD-L1 Status * *MSI-high TAP: tumor area positivity 15 Janjigian et al. ASCO Plenary Series, Nov. 7, 2023; data cut off of Sept. 4, 2023 © Arcus Biosciences 2024

  16. Slide 16: Landmark 6-Month PFS Compares Favorably to Benchmark Data

    Landmark 6-Month PFS Compares Favorably to Benchmark Data of 60-65%; Median PFS Still Immature Efficacy-Evaluable (N=41) PD-L1 High (TAP ≥5%, N=15) 6-month PFS = 77% 6-month PFS = 93% Median, months Month 6 Rate, % Median Follow-up Median, months Month 6 Rate, % Median Follow-up Events, n (%) Events

  17. Slide 17: Safety Profile for Dom + Zim + FOLFOX

    Safety Profile for Dom + Zim + FOLFOX Arm A1 TEAE N=41, n (%) Any Grade TEAEs ≥20% 70 Any TEAE 41 (100) Grade 1-2 60 Grade ≥3 TEAEs related to any study 40 (98) drug 50 Grade ≥3 TEAEs 28 (68) Patients, % 40 Grade ≥3 TEAEs related to any 23 (56) 49 study drug 30 54 2 2 2 Serious TEAEs 10 (24) 5 2 2 2

  18. Slide 18: Phase 3 Dom + Zim + Chemo vs Nivo + Chemo in 1L Gastric

    Phase 3 Evaluating Dom + Zim + Chemo vs Nivo + Chemo in 1L Gastric, GEJ and Esophageal Adenocarcinoma KEY ELIGIBILITY N=970 CRITERIA: DUAL PRIMARY ENDPOINTS: • 1L locally advanced unresectable or domvanalimab + zimberelimab + PI • OS ITT metastatic w/o prior choice of chemo* • OS in TAP ≥5% systemic

  19. Slide 19: Summary of ARC-7 Results and Dom Plus Zim Program in NSCLC

    Summary of ARC-7 Results and Domvanalimab Plus Zimberelimab Clinical Program in Non-Small Cell Lung Cancer Data presented at the 2023 ASCO Annual Meeting, based on data cut-off of Feb. 7, 2023. 19 © Arcus Biosciences 2024

  20. Slide 20: Randomized Phase 2 Study in 1L PD-L1-High NSCLC

    Randomized, Open-label, Ph2 Study in First-Line, Metastatic, PD-L1-High NSCLC ARM 1 STAGE IV NSCLC zim (Z) 360 mg IV Q3W KEY ELIGIBILITY: CO-PRIMARY ENDPOINTS • Treatment-naïve for • Investigator-assessed ORR & metastatic disease ARM 2 PFS per RECIST v1.1 R dom + zim (DZ) • PD-L1 ≥50%, locally 1:1:1

  21. Slide 21: Addition of Dom to Zim Resulted in 33% Reduction in Risk of Progression

    Addition of Dom to Zim Resulted in a 33% Reduction in Risk of Progression or Death, Compared to Zim Monotherapy CI: confidence interval; D/dom: domvanalimab; HR: hazard ratio; NE: not evaluable; PFS: progression- free survival; Z/zim: zimberelimab 21 Johnson et al. Abstract 397600, ASCO 2023; data c

  22. Slide 22: Phase 3 Dom + Zim + Chemo vs Pembro + Chemo in 1L NSCLC

    Phase 3 Evaluating Dom + Zim + Chemo vs. Pembro + Chemo in 1L NSCLC (All PD-L1 Subgroups) • Uses standard of care, pembrolizumab, in the comparator arm ELIGIBILITY CRITERIA: ARM A ENDPOINTS: • Metastatic NSCLC without dom + zim + platinum doublet PRIMARY actionable mutations (ARM A vs B) • No prior

  23. Slide 23: Phase 3 Dom + Durva vs Placebo + Durva in Stage III NSCLC

    Phase 3 Evaluating Dom + Durva vs Placebo + Durva in Unresectable, Stage III NSCLC • Combines domvanalimab (dom) with durvalumab (durva) standard-of-care in Stage III NSCLC • Potential to be first anti-TIGIT combination in this curative intent setting PATIENT POPULATION: ARM A (N=430) • Patients wit

  24. Slide 24: HIF-2α Program

    HIF-2α Program 24 © Arcus Biosciences 2024

  25. Slide 25: Value Proposition for Casdatifan, a Potential Best-in-Class HIF-2α Inhibitor

    Value Proposition for Casdatifan (AB521), a Potential Best- in-Class HIF-2α Inhibitor Efficacy Novel Combinations Opportunity to reach greater intra- Opportunity to create potentially best- tumoral HIF-2α inhibition compared in-class and first-in-class to 120 mg dose of belzutifan combinations • Req

  26. Slide 26: Preclinical Characterization Confirms Greater Potency of Casdatifan vs Belzutifan

    Extensive Preclinical Characterization Confirms Greater Potency of Casdatifan (AB521) Relative to that of Belzutifan ASSAY Casdatifan Belzutifana HIF-2α 786-O Luc Reporter 8.2 ± 2.5 (n=24) 16.9 ± 10.1 (n=8) IC50 (nM) Control 786-O Luc Reporter CELLULAR > 10,000 (n=6) > 10,000 (n=7) IC50 (nM) HIF-2α

  27. Slide 27: Casdatifan Monotherapy Dose Escalation/Expansion in ccRCC

    Casdatifan (AB521) Monotherapy Dose Escalation/ Expansion in ccRCC is Ongoing PH 1 DOSE ESCALATION EXPANSION COHORTS (2L+ ccRCC) 3+3 design with 21-day DLT window Solid-tumor patients w/o SOC KEY INCLUSION CRITERIA • At least 1 measurable lesion per 50mg (n=30) RECIST 1.1 Flexible language for COMPL

  28. Slide 28: Casdatifan 20mg Achieves Similar PD Effect as Belzutifan 120mg

    Casdatifan (AB521) 20mg Achieves Similar PD Effect as belzutifan at 120mg 20 mg of cas achieves near-complete suppression of Human PK profile of cas is dose-linear; HIF-2α-dependent EPO (peripheral PD marker); Daily 100mg cas dose expected to provide ~5x more 120mg of belzutifan (the approved dose)

  29. Slide 29: Hemoglobin Changes After Casdatifan 100 mg Similar to Belzutifan

    Hemoglobin Changes After Casdatifan (AB521) 100 mg Administration are Similar to that of Belzutifan at 120 mg Hemoglobin level (mean±SD) [g/dL] Cas, 50 mg daily (N≤15) Belz 120 mg daily, Male (N=29) Cas, 100 mg daily (N≤32) Belz 120 mg daily, Female (N=19) Hemoglobin change from baseline (mean±SD) [

  30. Slide 30: Treatment-Emergent Adverse Events

    Treatment-Emergent Adverse Events (as of Dec. 15, 2023) To date, rates of adverse events, including anemia and hypoxia, appear consistent with observations from historical trials of belzutifan. TEAEs Reported in ≥2 Patients Grade ≥3 TEAEs Dose Escalation Cohorts Dose Escalation Cohorts Preferred Ter

  31. Slide 31: Early Efficacy Signals in ccRCC Patients

    Early Efficacy Signals in ccRCC Patients Dose Escalation (n=4) Dose Expansion 100mg Cohort (n=30) • Meaningful clinical activity observed in 3 of the • Completed enrollment in Nov. 2023 4 ccRCC patients who had 2+ prior lines of • Majority of patients have had one or 2 scans, therapy equivalent to 1

  32. Slide 32: Phase 1b/2 Study of Casdatifan + Zanzalintinib +/- Nivolumab

    Phase 1b/2 Study of Casdatifan + Zanzalintinib +/- Nivolumab in Advanced Solid Tumors Including ccRCC* Primary Outcomes: DOSE FINDING DOSE EXPANSION Dose-Finding Stage: Inclusion: DLTs • ≥18 years Expansion Stage: • Unresectable advanced or metastatic disease or 1L or 2L+ ccRCC Cohort A: Cohort 1: O

  33. Slide 33: CD73-Adenosine Axis Programs

    CD73-Adenosine Axis Programs 33 © Arcus Biosciences 2024

  34. Slide 34: Etrumadenant in Pancreatic and Colorectal Cancers

    Etrumadenant in Pancreatic and Colorectal Cancers 34 © Arcus Biosciences 2024

  35. Slide 35: Etrumadenant: Potentially Best-in-Class Adenosine Receptor Antagonist

    Etrumadenant Represents a Potentially Best-in-Class Adenosine Receptor Antagonist ETRUMADENANT Etrumadenant has an ideal profile • Highly potent small molecule that inhibits both the A2a and A2b receptors  Retains potency in physiologically • Excellent penetration of tumor tissue relevant condition

  36. Slide 36: Summary of Results from MORPHEUS-PDAC

    Summary of Results from Phase Ib/II, Global, Open-Label, Randomized Evaluation of Atezolizumab (atezo) + Etrumadenant (etruma) + Chemotherapy (chemo) vs Chemo Alone in MORPHEUS-PDAC Data presented at AACR 2024, based on a data cutoff of January 12, 2023. 36 © Arcus Biosciences 2024

  37. Slide 37: Study Design – 1L Cohort

    MORPHEUS- PDAC Study Design –1L Cohort (operationalized by Roche) Screening Stage 1 Preliminary n=15 Expansion n=25 Other Combinations PD 1L Met Entry Biopsy PDAC Biopsy R Atezo + Gem/Nab-pac + etruma Gem/Nab-pac * Patients with PD on 1L cohort control arm (Gem/Abraxane) will have the option to enro

  38. Slide 38: Atezo+Gem/Nab-pac+Etruma Showed Durable Response and Stable Disease

    MORPHEUS- Atezo+Gem/Nab-pac+Etruma Showed Durable Response PDAC and Stable Disease Gem/Nab-pac Atezo+Gem/Nab-pac+Etruma 1L: first-line; atezo: atezolizumab; etruma: etrumadenant; Gem/Nab-pac: gemcitabine plus nab-paclitaxel; PDAC: pancreatic ductal adenocarcinoma Kim et al, AACR 2024, data cut off o

  39. Slide 39: Progression-Free Survival by Investigator per RECIST v1.1

    MORPHEUS- PDAC Progression-Free Survival by Investigator per RECIST v1.1 atezo: atezolizumab; etruma/AB928: etrumadenant; Gem/Nab-pac: gemcitabine plus nab-paclitaxel; HR: hazard ratio; NE: not evaluable; PDAC: pancreatic ductal adenocarcinoma Kim et al, AACR 2024, data cut off of Jan. 12, 2023 39 ©

  40. Slide 40: Overall Survival by Investigator per RECIST v1.1

    MORPHEUS- PDAC Overall Survival by Investigator per RECIST v1.1 atezo: atezolizumab; etruma/AB928: etrumadenant; Gem/Nab-pac: gemcitabine plus nab-paclitaxel; HR: hazard ratio; NE: not evaluable; PDAC: pancreatic ductal adenocarcinoma Kim et al, AACR 2024, data cut off of Jan. 12, 2023 40 © Arcus Bi

  41. Slide 41: Randomized Phase 2 Study of Etruma Plus Zim-Based Combinations in mCRC

    Randomized Phase 2 Study to Evaluate Etruma Plus Zim- Based Combinations in mCRC • Randomized Phase 2 study evaluating etruma + zim + chemo combinations vs. SOC in 2L & 3L mCRC • Mature PFS & OS data for Cohort B (3L; n=105) to be presented in oral presentation at ASCO 2024 (Abstract 3508) − Cohort

  42. Slide 42: Quemliclustat in Pancreatic Cancer

    Quemliclustat in Pancreatic Cancer 42 © Arcus Biosciences 2024

  43. Slide 43: Quemliclustat: Unique, Highly Potent, Selective CD73 Inhibitor

    Quemliclustat (quemli): A Unique, Highly Potent and Selective Small Molecule CD73 Inhibitor with Several Key Advantages QUEMLICLUSTAT • Highly potent small molecule Potential advantages over • Target coverage achieved at doses CD73 antibodies1 as low as 25 mg every two weeks • Extremely long (4+ day

  44. Slide 44: Final Overall Survival Analysis for Quemliclustat and Zimberelimab (ARC-8)

    Final Overall Survival Analysis for Quemliclustat and Zimberelimab in Pancreatic Cancer (ARC-8) Data presented at ASCO GI, January 19, 2024, based on a data cutoff of June 19, 2023. 44 © Arcus Biosciences 2024

  45. Slide 45: Highlights from ARC-8, a Phase 1b Study in 1L PDAC

    Highlights from the ARC-8, a Phase 1b Study in 1L PDAC Median overall survival (mOS) was 15.7 months for patients treated with a quemliclustat- based regimen, which exceeds the historical benchmark data for chemotherapy alone (8.5 – 11.7 months)1,2 A 37% reduction in risk of death and a 5.9-month im

  46. Slide 46: ARC-8 Study Design

    ARC-8 Study Design Included Dose Escalation, Expansion and Randomized Portions RANDOMIZATION DOSE ESCALATION DOSE EXPANSION (WITH AND WITHOUT ZIM) 125 mg quemli IV Q2W + G/nP + zim (n=3-6) COHORT A1 100 mg QZ + G/nP (n=61) COHORT A 100 mg quemli IV Q2W 1L mPDAC R + G/nP + zim (n=6) RDE 100 mg QZ + G

  47. Slide 47: Dataset Includes Four Groups of Patients Treated with 100 mg of Quemli

    Dataset Includes Four Groups of Patients Treated with 100 mg of Quemli Quemli Cohort Combination Participants Dosed >18m OS f/u? Population Dose Dose escalation 25 mg Q + Z + G/nP (quad) 4 Yes 1L mPDAC Dose escalation 50 mg Q + Z + G/nP (quad) 6 Yes 1L mPDAC Dose escalation 75 mg Q + Z + G/nP (quad)

  48. Slide 48: Demographics and Baseline Characteristics Well Balanced

    Demographics And Baseline Characteristics Are Well Balanced Across Arms & Efficacy-evaluated Populations % ECOG 1 (65%-69%) Was Higher than Historical G/nP Studies (42-57%); % Liver Mets (59%-69%) Was Slightly Lower than Historical G/nP Studies (78-85%) A2: Q + G/nP A1: QZ + G/nP Pooled Q100 QZ + G/

  49. Slide 49: 21-month Median Follow-up, OS Exceeds Ph3 Benchmarks

    With 21-month Median Follow-up, OS Results Exceed Ph3 Benchmarks for G/nP Phase 3 G/nP median OS G/nP Benchmarks1,2 Benchmark Median OS 8.5 – 11.1 months CI: confidence interval; G/nP: gemcitabine/nab-paclitaxel; Ph3: Phase 3 1. Abraxane USPI, 2020 and Wainberg ZA, Melisi D, Macarulla T, et al. NALI

  50. Slide 50: Favorable OS for Patients With & Without Liver Metastasis

    Favorable OS for Patients With & Without Liver Metastasis • Because ARC-8 had a lower incidence of liver mets than historical studies, we analyzed the OS for ARC-8 patients with and without liver mets as shown below • When adjusting for the lower incidence of liver mets in the triplet arm, mOS for t

  51. Slide 51: Safety Profile Similar to G/nP

    Safety Profile Similar to G/nP with Regards to Overall TEAEs NAPOLI-3 G/nP A2: Q + G/nP Pooled Q100 QZ + G/nP All Pooled Q100 Q % Benchmark4 (n=29) (n=93) (±Z)+G/nP (n=122) (n=379) Any TEAE 100 100 100 99 Any TRAE 100 98.9 99.2 93 Grade 3-5 TEAE 89.7 83.9 85.2 86 Grade 3-5 TRAE 75.9 72.0 73.0 68 Ser

  52. Slide 52: Arcus & Medidata AI Synthetic Control Arm Project

    Arcus & Medidata AI Synthetic Control Arm (SCA) Project • Developed in collaboration with Medidata, the industry’s leading provider of electronic data capture for clinical trials • Constructed SCA using historical data from patients treated with G/nP alone and balanced to the patient baseline charac

  53. Slide 53: Quemli Regimen Reduced Risk of Death by 37% vs SCA

    Quemli-based Regimen Reduced Risk of Death by 37% and increased mOS by 5.9 months Compared to SCA CI: confidence interval; mOS: median overall survival; quemli: quemliclustat; SCA: Synthetic Control Arm 53 Wainberg ZA, et al. ASCO GI, Jan. 19, 2024, data cut off of June 19, 2023 © Arcus Biosciences

  54. Slide 54: AXL Program

    AXL Program 54 © Arcus Biosciences 2024

  55. Slide 55: AXL Signaling is a Common Mechanism of Resistance

    AXL Signaling is a Common Mechanism of Resistance to Chemotherapy and Immunotherapy in Tumors AXL signals via Ligand-dependent and Ligand-independent mechanisms THERAPEUTIC HYPOTHESIS: AXL inhibition will overcome multiple mechanisms of drug-resistance MERTK EGFR TYRO3 VEGFR HER2 AB801 sensitizes ca

  56. Slide 56: AB801 is a Potent, Selective, and Efficacious AXL Inhibitor

    AB801 is a Potent, Selective, and Efficacious AXL Inhibitor Combination of AB801 with Oxaliplatin & α-PD-1 AB801 is a highly potent Increases Anti-Tumor Efficacy and Survival and selective AXL inhibitor in Preclinical Models* Assay AB801 AXL Ki 0.024 nM 3000 Oxaliplatin Stopped 100 Stopped Treatment

  57. Slide 57: AB801 Potentially Most Potent & Selective AXL Inhibitor in Clinical Development

    AB801 is Potentially the Most Potent & Selective AXL Inhibitor in Clinical Development THERAPEUTIC HYPOTHESIS: Inhibiting AXL will overcome resistance against chemotherapy and immunotherapy in human tumors • AB801 was designed to potently and selectively inhibit AXL signaling in tumors, resulting in

  58. Slide 58: Phase 1 Dose-Finding Study in Advanced Solid Tumors

    Phase 1 Dose-Finding Study in Patients with Advanced Solid Tumors PRE-SCREENING / SCREENING DOSE ESCALATION STAGE EXPANSION STAGE DOSE ESCALATION PRIMARY ENDPOINT • Safety / DLT AB801 SECONDARY ENDPOINT • PK • ORR AB801 EXPLORATORY ENDPOINTS Advanced Solid Cohort 1: NSCLC • Biomarkers / PD Tumors AB

  59. Slide 59: Appendix

    APPENDIX 59 © Arcus Biosciences 2024

  60. Slide 60: Diverse Pipeline with Multiple Molecules in Late-Stage Development

    Diverse Pipeline with Multiple Molecules in Late-Stage Development MOLECULE INDICATION STUDY PHASE 1 PHASE 1B PHASE 2 PHASE 3 Perioperative lung cancer (in planning) dom + zim + chemo → dom + zim Stage III, unresectable, PD-L1≥1% NSCLC dom + durvalumab vs durvalumab DOMVANALIMAB (DOM) 1L NSCLC, PD-L

  61. Slide 61: Domvanalimab: Most Clinically Advanced Fc-Silent TIGIT Antibody

    Domvanalimab (dom): Most Clinically Advanced Fc-Silent TIGIT Antibody in Clinical Development IMMUNOSUPPRESSION IMMUNE CELL ACTIVATION & TUMOR CELL KILLING T or NK cell T or NK cell PD-1 TIGIT TIGIT Zimberelimab PD-1 CD226 Cytotoxic CD226 proteins PD-L1 released CD155 domvanalimab PD-L1 CD155 Tumor

  62. Slide 62: HIF-2α Regulates Multiple Facets of Cancer Cell Biology

    HIF-2α Regulates Multiple Facets of Cancer Cell Biology SDH: Succinate dehydrogenase; VHL: Von Hippel-Lindau 62 © Arcus Biosciences 2024

  63. Slide 63: Casdatifan in the Cancer Cell Nucleus

    Casdatifan (HIF-2a inhibitor) in the Cancer Cell Nucleus 1 In many cancers, the 3 Cas binds to HIF-2α transcription factor HIF-2α is dysregulated, allowing it to casdatifan The highly specific small molecule cas can translocate freely to the penetrate cells and bind cancer cell nucleus. HIF-2α. HIF-

  64. Slide 64: CD73-Adenosine Axis in Immune Response Suppression

    The CD73-Adenosine Axis Plays a Well-Established and Critical Role in Suppression of the Immune Response NK Cells ATP ↓ cytotoxicity etrumadenant blocks adenosine from binding to A2aR and A2bR, 1 ATP is released from blocking immunosuppression A2a tumor cells in A2b Receptor response to cellular Rec

  65. Slide 65: Platform Design to Rapidly Evaluate Novel Combinations for NSCLC

    Platform Design to Rapidly Evaluate Novel Combinations for NSCLC, Including Quemli and Dom-based Regimens PRELIMINARY STAGE EXPANSION PRE-SCREENING SCREENING (N=20/30) STAGE PRIMARY ENDPOINTS • ORR • Safety and tolerability EXPERIMENTAL SUB-STUDY A TREATMENT ARMS Treatment arm(s) SECONDARY 1L, metas

  66. Slide 66: Combining to Cure

    RCUS BIOSCIENCES COMBINING TO CURE”

Arcus Biosciences — Q1 2024 Earnings Presentation on 6ix